huC242-DM1

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Purpose:To assess safety, pharmacokinetics, maximum tolerated dose, and preliminary efficacy of bivatuzumab mertansine… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 4
Is this relevant?
2004
2004
The humanized monoclonal antibody maytansinoid conjugate, cantuzumab mertansine (huC242-DM1) that contains on average three to… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2003
2003
L'invention concerne une formulation stable destinee a huC242-DM1, un anticorps conjugue a un agent cytotoxique. 
Is this relevant?
2001
2001
C242-DM1 is a tumor-activated immunotoxin under development by GlaxoSmithKline plc (formerly SmithKline Beecham plc), under… Expand
Is this relevant?